These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 12198643

  • 1. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G, Beuers U.
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [Abstract] [Full Text] [Related]

  • 2. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
    Beuers U.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
    [Abstract] [Full Text] [Related]

  • 3. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.
    Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G, Dombrowski F.
    Hepatology; 2001 May; 33(5):1206-16. PubMed ID: 11343250
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.
    Paumgartner G, Beuers U.
    Clin Liver Dis; 2004 Feb; 8(1):67-81, vi. PubMed ID: 15062194
    [Abstract] [Full Text] [Related]

  • 5. New therapeutical indications of ursodeoxycholic acid.
    Copaci I, Micu L, Iliescu L, Voiculescu M.
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [Abstract] [Full Text] [Related]

  • 6. [Cholestatic liver diseases].
    Reichel C, Meier-Abt PJ.
    Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
    [Abstract] [Full Text] [Related]

  • 7. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver.
    Wimmer R, Hohenester S, Pusl T, Denk GU, Rust C, Beuers U.
    Gut; 2008 Oct; 57(10):1448-54. PubMed ID: 18583398
    [Abstract] [Full Text] [Related]

  • 8. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
    Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundström R, Gustafsson U, Sahlin S, Einarsson C, Trauner M.
    Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
    [Abstract] [Full Text] [Related]

  • 9. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
    Festi D, Montagnani M, Azzaroli F, Lodato F, Mazzella G, Roda A, Di Biase AR, Roda E, Simoni P, Colecchia A.
    Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
    [Abstract] [Full Text] [Related]

  • 10. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A, Rudolph G, Sauer P, Theilmann L.
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [Abstract] [Full Text] [Related]

  • 11. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T, Beuers U.
    World J Gastroenterol; 2006 Jun 14; 12(22):3487-95. PubMed ID: 16773706
    [Abstract] [Full Text] [Related]

  • 12. [Cholestasis: therapeutic options].
    Beuers U, Oswald M.
    Ther Umsch; 1998 Feb 14; 55(2):97-103. PubMed ID: 9545851
    [Abstract] [Full Text] [Related]

  • 13. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
    Luketic VA, Sanyal AJ.
    Gastroenterologist; 1994 Mar 14; 2(1):74-9. PubMed ID: 8055235
    [Abstract] [Full Text] [Related]

  • 14. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.
    Alpini G, Baiocchi L, Glaser S, Ueno Y, Marzioni M, Francis H, Phinizy JL, Angelico M, Lesage G.
    Hepatology; 2002 May 14; 35(5):1041-52. PubMed ID: 11981754
    [Abstract] [Full Text] [Related]

  • 15. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
    Lirussi F, Okolicsanyi L.
    Ital J Gastroenterol; 1992 Jan 14; 24(1):31-5. PubMed ID: 1571577
    [Abstract] [Full Text] [Related]

  • 16. [Bile acids in liver diseases--current indications].
    Stiehl A.
    Ther Umsch; 1995 Oct 14; 52(10):682-6. PubMed ID: 7482380
    [Abstract] [Full Text] [Related]

  • 17. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
    Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sánchez Pozzi EJ.
    Clin Sci (Lond); 2011 Dec 14; 121(12):523-44. PubMed ID: 21854363
    [Abstract] [Full Text] [Related]

  • 18. Use of ursodeoxycholic acid in patients with liver disease.
    Angulo P.
    Curr Gastroenterol Rep; 2002 Feb 14; 4(1):37-44. PubMed ID: 11825540
    [Abstract] [Full Text] [Related]

  • 19. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
    Mazzella G, Rizzo N, Azzaroli F, Simoni P, Bovicelli L, Miracolo A, Simonazzi G, Colecchia A, Nigro G, Mwangemi C, Festi D, Roda E.
    Hepatology; 2001 Mar 14; 33(3):504-8. PubMed ID: 11230728
    [Abstract] [Full Text] [Related]

  • 20. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
    Olsson R.
    Lakartidningen; 2002 Mar 21; 99(12):1325-30. PubMed ID: 11998165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.